


Rec'd PCT/PTO 16 DEC 2005

TH
PATENT
ATTORNEY DOCKET NO. 00786/436002

Certificate of Mailing	
Date of Deposit: <u>December 16, 2005</u>	Label Number: <u>EV 768764368 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Elvis DeLaCruz</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ruvkun and Frand Art Unit: Not Yet Assigned
Serial No.: 10/540,445 Examiner: Not Yet Assigned
Filed: June 22, 2005 Customer No.: 21559
Title: METHODS AND COMPOSITIONS OF ECDYSOZOAN MOLT INHIBITION

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. §§ 1.821 THROUGH 1.825

In reply to the Notification of Missing Requirements Under 35 U.S.C. § 371 that was mailed in connection with the above-captioned application on October 24, 2005, and in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825, enclosed is a Sequence Listing consisting of seven (7) sheets. I hereby submit that these sheets contain no new matter.

As required by 37 C.F.R. § 1.821(c), the Sequence Listing appears as a separate part of the application. Each sequence in the application appears separately in the

Sequence Listing, and each sequence in the Sequence Listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the Sequence Listing in computer readable form.


As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form of the Sequence Listing are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 16 December 2005


Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045